Trials / Completed
CompletedNCT02737787
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | WT1 Vaccine | |
| DRUG | Nivolumab | Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12. |
| BIOLOGICAL | NY-ESO-1 Vaccine | Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2023-04-06
- Completion
- 2023-04-06
- First posted
- 2016-04-14
- Last updated
- 2023-04-07
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02737787. Inclusion in this directory is not an endorsement.